Evidenced-based guidelines for tuberculosis screening before biologic treatment initiation - 19/06/20
Doi : 10.1016/j.jaad.2020.02.084
Payal Shah, BS a, ⁎ 
, Gabriel Rebick, MD b, Shirin Bajaj, MD a, Ludovic Desvignes, MD b, Kristen Lo Sicco, MD a
, Gabriel Rebick, MD b, Shirin Bajaj, MD a, Ludovic Desvignes, MD b, Kristen Lo Sicco, MD a a The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York
b Department of Medicine, Division of Infectious Diseases and Immunology, New York University Langone Health, New York, New York
∗Correspondence to: Payal Shah, BS, The Ronald O. Perelman Department of Dermatology, New York University Langone Health, 240 East 38th St, 11th Floor, New York, NY 10016The Ronald O. Perelman Department of DermatologyNew York University Langone Health240 East 38th St11th FloorNew YorkNY10016
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 83 - N° 1
P. e25-e26 - luglio 2020 Ritorno al numero
Articolo precedente
- Reply to: “Comment on ‘Dermatomyositis—Clinical features and pathogenesis’”
- Madeline E. DeWane, Reid Waldman, Jun Lu
- Reply to: “Evidence-based guidelines for tuberculosis screening before biologic treatment initiation”
- Anthony P. Fernandez, Ariana Ellis, Urmi Khanna, AbdulAziz Galadari
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?